Cohort profile: the Oxford Parkinson’s Disease Centre Discovery Cohort MRI substudy (OPDC-MRI)

<p><strong>Purpose:</strong> The Oxford Parkinson’s Disease Centre (OPDC) Discovery Cohort MRI substudy (OPDC-MRI) collects high-quality multimodal brain MRI together with deep longitudinal clinical phenotyping in patients with Parkinson’s, at-risk individuals and healthy elderly p...

Full description

Bibliographic Details
Main Authors: Griffanti, L, Klein, JC, Szewczyk-Krolikowski, K, Menke, R, Rolinski, M, Barber, T, Lawton, M, Evetts, S, Begeti, F, Crabbe, M, Rumbold, J, Wade-Martins, R, Hu, M, Mackay, C
Format: Journal article
Language:English
Published: BMJ Publishing Group 2020
_version_ 1797071668182515712
author Griffanti, L
Klein, JC
Szewczyk-Krolikowski, K
Menke, R
Rolinski, M
Barber, T
Lawton, M
Evetts, S
Begeti, F
Crabbe, M
Rumbold, J
Wade-Martins, R
Hu, M
Mackay, C
author_facet Griffanti, L
Klein, JC
Szewczyk-Krolikowski, K
Menke, R
Rolinski, M
Barber, T
Lawton, M
Evetts, S
Begeti, F
Crabbe, M
Rumbold, J
Wade-Martins, R
Hu, M
Mackay, C
author_sort Griffanti, L
collection OXFORD
description <p><strong>Purpose:</strong> The Oxford Parkinson’s Disease Centre (OPDC) Discovery Cohort MRI substudy (OPDC-MRI) collects high-quality multimodal brain MRI together with deep longitudinal clinical phenotyping in patients with Parkinson’s, at-risk individuals and healthy elderly participants. The primary aim is to detect pathological changes in brain structure and function, and develop, together with the clinical data, biomarkers to stratify, predict and chart progression in early-stage Parkinson’s and at-risk individuals.</p> <p><strong>Participants:</strong> Participants are recruited from the OPDC Discovery Cohort, a prospective, longitudinal study. Baseline MRI data are currently available for 290 participants: 119 patients with early idiopathic Parkinson’s, 15 Parkinson’s patients with pathogenic mutations of the leucine-rich repeat kinase 2 or glucocerebrosidase (GBA) genes, 68 healthy controls and 87 individuals at risk of Parkinson’s (asymptomatic carriers of GBA mutation and patients with idiopathic rapid eye movement sleep behaviour disorder-RBD).</p> <p><strong>Findings to date:</strong> Differences in brain structure in early Parkinson’s were found to be subtle, with small changes in the shape of the globus pallidus and evidence of alterations in microstructural integrity in the prefrontal cortex that correlated with performance on executive function tests. Brain function, as assayed with resting fMRI yielded more substantial differences, with basal ganglia connectivity reduced in early Parkinson’sand RBD. Imaging of the substantia nigra with the more recent adoption of sequences sensitive to iron and neuromelanin content shows promising results in identifying early signs of Parkinsonian disease.</p> <p><strong>Future plans:</strong> Ongoing studies include the integration of multimodal MRI measures to improve discrimination power. Follow-up clinical data are now accumulating and will allow us to correlate baseline imaging measures to clinical disease progression. Follow-up MRI scanning started in 2015 and is currently ongoing, providing the opportunity for future longitudinal imaging analyses with parallel clinical phenotyping.</p>
first_indexed 2024-03-06T22:56:42Z
format Journal article
id oxford-uuid:60a549f5-c351-4060-94aa-b927319d65bf
institution University of Oxford
language English
last_indexed 2024-03-06T22:56:42Z
publishDate 2020
publisher BMJ Publishing Group
record_format dspace
spelling oxford-uuid:60a549f5-c351-4060-94aa-b927319d65bf2022-03-26T17:54:40ZCohort profile: the Oxford Parkinson’s Disease Centre Discovery Cohort MRI substudy (OPDC-MRI)Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:60a549f5-c351-4060-94aa-b927319d65bfEnglishSymplectic ElementsBMJ Publishing Group2020Griffanti, LKlein, JCSzewczyk-Krolikowski, KMenke, RRolinski, MBarber, TLawton, MEvetts, SBegeti, FCrabbe, MRumbold, JWade-Martins, RHu, MMackay, C<p><strong>Purpose:</strong> The Oxford Parkinson’s Disease Centre (OPDC) Discovery Cohort MRI substudy (OPDC-MRI) collects high-quality multimodal brain MRI together with deep longitudinal clinical phenotyping in patients with Parkinson’s, at-risk individuals and healthy elderly participants. The primary aim is to detect pathological changes in brain structure and function, and develop, together with the clinical data, biomarkers to stratify, predict and chart progression in early-stage Parkinson’s and at-risk individuals.</p> <p><strong>Participants:</strong> Participants are recruited from the OPDC Discovery Cohort, a prospective, longitudinal study. Baseline MRI data are currently available for 290 participants: 119 patients with early idiopathic Parkinson’s, 15 Parkinson’s patients with pathogenic mutations of the leucine-rich repeat kinase 2 or glucocerebrosidase (GBA) genes, 68 healthy controls and 87 individuals at risk of Parkinson’s (asymptomatic carriers of GBA mutation and patients with idiopathic rapid eye movement sleep behaviour disorder-RBD).</p> <p><strong>Findings to date:</strong> Differences in brain structure in early Parkinson’s were found to be subtle, with small changes in the shape of the globus pallidus and evidence of alterations in microstructural integrity in the prefrontal cortex that correlated with performance on executive function tests. Brain function, as assayed with resting fMRI yielded more substantial differences, with basal ganglia connectivity reduced in early Parkinson’sand RBD. Imaging of the substantia nigra with the more recent adoption of sequences sensitive to iron and neuromelanin content shows promising results in identifying early signs of Parkinsonian disease.</p> <p><strong>Future plans:</strong> Ongoing studies include the integration of multimodal MRI measures to improve discrimination power. Follow-up clinical data are now accumulating and will allow us to correlate baseline imaging measures to clinical disease progression. Follow-up MRI scanning started in 2015 and is currently ongoing, providing the opportunity for future longitudinal imaging analyses with parallel clinical phenotyping.</p>
spellingShingle Griffanti, L
Klein, JC
Szewczyk-Krolikowski, K
Menke, R
Rolinski, M
Barber, T
Lawton, M
Evetts, S
Begeti, F
Crabbe, M
Rumbold, J
Wade-Martins, R
Hu, M
Mackay, C
Cohort profile: the Oxford Parkinson’s Disease Centre Discovery Cohort MRI substudy (OPDC-MRI)
title Cohort profile: the Oxford Parkinson’s Disease Centre Discovery Cohort MRI substudy (OPDC-MRI)
title_full Cohort profile: the Oxford Parkinson’s Disease Centre Discovery Cohort MRI substudy (OPDC-MRI)
title_fullStr Cohort profile: the Oxford Parkinson’s Disease Centre Discovery Cohort MRI substudy (OPDC-MRI)
title_full_unstemmed Cohort profile: the Oxford Parkinson’s Disease Centre Discovery Cohort MRI substudy (OPDC-MRI)
title_short Cohort profile: the Oxford Parkinson’s Disease Centre Discovery Cohort MRI substudy (OPDC-MRI)
title_sort cohort profile the oxford parkinson s disease centre discovery cohort mri substudy opdc mri
work_keys_str_mv AT griffantil cohortprofiletheoxfordparkinsonsdiseasecentrediscoverycohortmrisubstudyopdcmri
AT kleinjc cohortprofiletheoxfordparkinsonsdiseasecentrediscoverycohortmrisubstudyopdcmri
AT szewczykkrolikowskik cohortprofiletheoxfordparkinsonsdiseasecentrediscoverycohortmrisubstudyopdcmri
AT menker cohortprofiletheoxfordparkinsonsdiseasecentrediscoverycohortmrisubstudyopdcmri
AT rolinskim cohortprofiletheoxfordparkinsonsdiseasecentrediscoverycohortmrisubstudyopdcmri
AT barbert cohortprofiletheoxfordparkinsonsdiseasecentrediscoverycohortmrisubstudyopdcmri
AT lawtonm cohortprofiletheoxfordparkinsonsdiseasecentrediscoverycohortmrisubstudyopdcmri
AT evettss cohortprofiletheoxfordparkinsonsdiseasecentrediscoverycohortmrisubstudyopdcmri
AT begetif cohortprofiletheoxfordparkinsonsdiseasecentrediscoverycohortmrisubstudyopdcmri
AT crabbem cohortprofiletheoxfordparkinsonsdiseasecentrediscoverycohortmrisubstudyopdcmri
AT rumboldj cohortprofiletheoxfordparkinsonsdiseasecentrediscoverycohortmrisubstudyopdcmri
AT wademartinsr cohortprofiletheoxfordparkinsonsdiseasecentrediscoverycohortmrisubstudyopdcmri
AT hum cohortprofiletheoxfordparkinsonsdiseasecentrediscoverycohortmrisubstudyopdcmri
AT mackayc cohortprofiletheoxfordparkinsonsdiseasecentrediscoverycohortmrisubstudyopdcmri